β-defensin 133 Inhibitors
β-defensin 133 Inhibitors represent a class of compounds targeting specific cellular pathways involved in the expression of the β-defensin 133 gene. These inhibitors act on key signaling molecules, disrupting the intricate network that culminates in the activation of β-defensin 133. Wortmannin and LY294002, for instance, are PI3K inhibitors that impede the PI3K/Akt pathway, vital for the transcription of β-defensin 133. Rapamycin, SB203580, U0126, and SP600125 target mTOR, p38 MAPK, MEK1/2, and JNK, respectively, interfering with their respective pathways linked to β-defensin 133 regulation. Dual inhibitors like PI-103 simultaneously act on PI3K and mTOR, reinforcing the inhibition. PD98059, SB202190, TGX-221, AZD8055, and SP100030 contribute to β-defensin 133 inhibition by targeting the MEK/ERK, p38 MAPK, PI3K, mTOR, and JNK pathways, respectively. This array of inhibitors offers a versatile toolkit for researchers studying the intricate regulatory mechanisms controlling β-defensin 133 expression, providing valuable insights into interventions in a broader biological context.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits β-defensin 133 by targeting PI3K, disrupting the PI3K/Akt signaling pathway crucial for gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 acts as a PI3K inhibitor, disrupting downstream signals that would otherwise stimulate β-defensin 133 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key player in the mTORC1 signaling pathway linked to β-defensin 133 activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 impedes p38 MAPK, affecting downstream elements in signaling cascades influencing β-defensin 133 transcription. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, blocking ERK phosphorylation and interfering with the MAPK/ERK pathway involved in β-defensin 133. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 hinders JNK, disrupting the JNK signaling pathway, which plays a role in regulating β-defensin 133 expression. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 targets both PI3K and mTOR, creating a dual inhibitory effect on pathways associated with β-defensin 133 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 blocks MEK/ERK signaling, inhibiting the cascade that influences β-defensin 133 expression. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $86.00 $153.00 $275.00 $452.00 | 3 | |
SB202190 acts as a p38 MAPK inhibitor, disrupting the signaling events that lead to β-defensin 133 upregulation. | ||||||
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
TGX-221 inhibits PI3K, affecting the PI3K/Akt pathway and subsequently impeding β-defensin 133 expression. | ||||||